Roche Announces Changes to Board of Directors - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Roche Announces Changes to Board of Directors



Roche has proposed that the following members of its board of directors be re-elected at the company’s annual general meeting, scheduled for March 4, 2014.

André Hoffmann, member since 1996; Dr. Andreas Oeri, member since 1996; Prof. Dr. Pius Baschera, member since 2007; Prof. Sir John Irving Bell, member since 2001; Paul Bulcke, member since 2011; Dr. Christoph Franz, member since 2011; Dame DeAnne Julius, member since 2002; Dr. Arthur D. Levinson, member since  2010; Dr. Severin Schwan, member since 2013; Peter R. Voser, member since 2011; Prof. Dr. Beatrice Weder di Mauro, member since 2006.

As announced on Sept. 16, 2013, the board proposes Christoph Franz to be elected as chairman of the board.

William M. Burns, member of the board of directors since 2010, has announced that he will not stand for re-election to the board of directors.

Source: Roche

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here